The latest update is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited has announced the quotation of 115,600,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of March 27, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations, which could positively impact its stakeholders and industry positioning.
More about Bioxyne Limited
Bioxyne Limited operates in the biotechnology industry, focusing on the development and commercialization of health and wellness products. The company is primarily involved in producing probiotic and immune health products, targeting both domestic and international markets.
YTD Price Performance: -10.0%
Average Trading Volume: 3,483,006
Technical Sentiment Signal: Sell
Current Market Cap: A$55.33M
See more data about BXN stock on TipRanks’ Stock Analysis page.